Wolk David A, Grachev Igor D, Buckley Chris, Kazi Hala, Grady M Sean, Trojanowski John Q, Hamilton Roy H, Sherwin Paul, McLain Richard, Arnold Steven E
Penn Memory Center, 3615 Chestnut St, Philadelphia, PA 19104, USA.
Arch Neurol. 2011 Nov;68(11):1398-403. doi: 10.1001/archneurol.2011.153. Epub 2011 Jul 11.
To determine the correspondence of in vivo quantitative estimates of brain uptake of fluorine 18-labeled flutemetamol with immunohistochemical estimates of amyloid levels in patients who underwent previous biopsy.
Cross-sectional study of ¹⁸F-flutemetamol positron emission tomography (PET) findings in patients with prior cortical biopsy specimen stained for the presence or absence of amyloid plaques.
University hospital. Patients Seven patients who previously had a prior right frontal cortical biopsy at the site of ventriculoperitoneal placement for presumed normal pressure hydrocephalus were recruited. Inclusion criteria included an adequate biopsy specimen for detection and quantification of β-amyloid pathology and age older than 50 years. Intervention All patients underwent an ¹⁸F-flutemetamol PET scan.
Quantitative measures of ¹⁸F-flutemetamol uptake (standardized uptake value ratio, a ratio of mean target cortex activity divided by that in a cerebellar reference region) were made at a location contralateral to the biopsy site and compared with estimates of amyloid load based on immunohistochemical and histological staining.
There was complete agreement between visual reads of ¹⁸F-flutemetamol PET scans (3 blinded readers with majority rule) and histology. A regression model, including time from biopsy as a covariate, demonstrated a significant relationship (P = .01) between ¹⁸F-flutemetamol uptake and percentage of area of amyloid measured by a monoclonal antibody raised against amyloid (NAB228). Similar results were found with the amyloid-specific monoclonal antibody 4G8 and Thioflavin S.
To our knowledge, these data are the first to demonstrate the concordance of ¹⁸F-flutemetamol PET imaging with histopathology, supporting its sensitivity to detect amyloid and potential use in the study and detection of Alzheimer disease.
确定在先前接受活检的患者中,氟-18标记的氟代米他莫尔脑摄取的体内定量估计值与淀粉样蛋白水平的免疫组织化学估计值之间的对应关系。
对先前皮质活检标本进行淀粉样斑块染色的患者进行¹⁸F-氟代米他莫尔正电子发射断层扫描(PET)结果的横断面研究。
大学医院。患者招募了7名先前因疑似正常压力脑积水在脑室腹腔分流部位进行过右侧额叶皮质活检的患者。纳入标准包括有足够的活检标本用于检测和定量β-淀粉样蛋白病理学,且年龄大于50岁。干预所有患者均接受¹⁸F-氟代米他莫尔PET扫描。
在活检部位对侧的位置进行¹⁸F-氟代米他莫尔摄取的定量测量(标准化摄取值比率,即平均目标皮质活性与小脑参考区域活性的比率),并与基于免疫组织化学和组织学染色的淀粉样蛋白负荷估计值进行比较。
¹⁸F-氟代米他莫尔PET扫描的视觉读数(3名盲法读者采用多数裁定法)与组织学结果完全一致。一个回归模型,将活检后的时间作为协变量,显示¹⁸F-氟代米他莫尔摄取与用抗淀粉样蛋白单克隆抗体(NAB228)测量的淀粉样蛋白面积百分比之间存在显著关系(P = 0.01)。使用淀粉样蛋白特异性单克隆抗体4G8和硫黄素S也发现了类似结果。
据我们所知,这些数据首次证明了¹⁸F-氟代米他莫尔PET成像与组织病理学的一致性,支持其在检测淀粉样蛋白方面的敏感性以及在阿尔茨海默病研究和检测中的潜在用途。